Kolon Life Science Inc. (KOSDAQ:102940)

South Korea flag South Korea · Delayed Price · Currency is KRW
31,500
-450 (-1.41%)
Aug 8, 2025, 3:30 PM KST
-1.41%
Market Cap396.93B
Revenue (ttm)167.66B
Net Income (ttm)-78.06B
Shares Out12.42M
EPS (ttm)-6,510.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,628
Average Volume23,530
Open31,950
Previous Close31,950
Day's Range31,150 - 32,300
52-Week Range16,780 - 39,400
Beta-0.08
RSI44.01
Earnings DateAug 13, 2025

About VMware

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2000
Employees 426
Stock Exchange KOSDAQ
Ticker Symbol 102940
Full Company Profile

Financial Performance

In 2024, Kolon Life Science's revenue was 161.39 billion, an increase of 29.48% compared to the previous year's 124.64 billion. Losses were -93.09 billion, 203.0% more than in 2023.

Financial Statements

News

There is no news available yet.